Pharmacology of Antiplatelet Agents: Aspirin, PDE Inhibitors, ADP Receptor Blockers, and GP IIb/IIIa Antagonists

Platelet Lifespan and Irreversibility: * Platelets do not have DNA and therefore cannot reproduce the Cyclooxygenase (COX) enzyme once it has been inhabited. * Aspirin knocks out COX-1 activity for the entire life of that specific platelet, which ranges from approximately $7$ to $10$ days.
Metabolism and Half-Life: * Aspirin is very rapidly hydrolyzed in the body into salicylic acid and acetate. * This hydrolysis is carried out by esterases present in both the tissue and the blood. * The half-life of aspirin in the body is approximately $15\,minutes$ .
Absorption and Hepatic First-Pass Effect: * Aspirin is administered orally. * Upon absorption, it travels first to the liver via the hepatic portal vein. * Approximately $75\%$ of the dose is metabolized in the liver (first-pass metabolism).
The Low-Dose Aspirin Strategy: * With low-dose aspirin, very little of the drug reaches the systemic circulation. * Mechanism in the Portal Vein: Aspirin targets platelets in the blood within the hepatic portal vein immediately after absorption. * These platelets are affected before the drug reaches the liver; once inactivated, these platelets will circulate throughout the entire body. * Because very little drug survives the liver to enter systemic circulation, systemic adverse effects are minimized.

Nonselective Inhibition: Aspirin is a nonselective inhibitor of both COX-1 and COX-2.
COX-1 (Constitutively Expressed) Functions: * Platelets: Produces Thromboxane $A_2$ ( $TXA_2$ ), which promotes platelet activation and aggregation. * Stomach (Prostaglandin A2): Causes vasodilation, increases mucus production, and decreases acid and pepsin secretion. These are protective effects. * Kidney: Causes arterial dilation and decreases sodium reabsorption.
COX-2 (Inflammatory/Induced) Functions: * Inflammation: Involved in pain, fever, and the inflammatory response. * Prostacyclin (Prostaglandin I2): Produced by COX-2; it inhibits platelet aggregation (opposite of $TXA_2$ ). * Kidney Stress Response: While COX-1 is the primary enzyme in normal kidney function, COX-2 is upregulated and becomes more important when the kidney is under stress, regulating arterial dilation and sodium reabsorption.
Adverse Effects of Systemic Inhibition (High Dose): * Stomach: Inhibition of Prostaglandin A2 leads to indigestion, ulceration, and bleeding. * Kidney: Inhibition leads to fluid retention and increased sodium reabsorption. * Prothrombotic Risk: Knocking out Prostacyclin ( $PGI_2$ ) can create a prothrombotic environment.

Selective Antiplatelet Effect of Low-Dose: * At low doses, only Thromboxane $A_2$ is significantly knocked out. The main adverse effect is bleeding if antiplatelet activity is excessive.
The Impact of High-Dose Aspirin on the "Antiplatelet Balance": * Higher doses result in systemic exposure, which inhibits Prostacyclin ( $PGI_2$ ) production by endothelial cells in the vasculature. * Regeneration in Endothelial Cells: Unlike platelets, endothelial cells have DNA. They can produce more COX-2 and subsequently more Prostacyclin once the aspirin (which has a short half-life) is cleared. The knockout of Prostacyclin is therefore temporary. * Permanent Knockout in Platelets: Platelets remain permanently inactivated because they lack DNA. * Reduced Overall Efficacy: Because systemic high-dose aspirin inhibits the anti-aggregatory Prostacyclin, it can offset some of the benefits of knocking out Thromboxane $A_2$ . Thus, low-dose aspirin is paradoxically more effective as an antiplatelet agent than high-dose aspirin.

Mechanism of Action: * Dipyridamole inhibits the enzyme phosphodiesterase. * This inhibition leads to an increase in cyclic AMP ( $cAMP$ ) within the platelet, which ultimately decreases platelet activation and aggregation.
Adenosine Reuptake Inhibition: * Dipyridamole inhibits the reuptake of adenosine by platelets and other cells. * This results in more extracellular adenosine, which binds to platelet adenosine receptors, further increasing cyclic AMP production.
Clinical Profile: * It has a relatively weak antiplatelet effect. * It possesses vasodilator properties, which can lead to side effects such as hypotension and headaches (the latter occurring in approximately $10\%$ of patients).

Mechanism of Action: * These drugs target the $P_2Y$ ADP receptor on the platelet surface. * ADP binding is crucial for platelet activation and the upregulation of Glycoprotein IIb/IIIa ( $GP\,IIb/IIIa$ ) integrins. * Blocking this receptor decreases platelet activation and aggregation.
Drug Comparisons: 1. Clopidogrel: * Type: Pro-drug. * Activation: Requires two $CYP450$ -dependent steps. * Binding: Irreversible. * Onset: $2$ to $4\,hours$ . * Duration: Up to $10\,days$ . * Dosing: Once daily (a dose of $75\,mg$ achieves maximal inhibition). 2. Prasugrel: * Type: Pro-drug. * Activation: Hydrolyzed by plasma esterases followed by one $CYP450$ -dependent step. * Binding: Irreversible. * Onset: $30\,minutes$ . * Duration: Up to $10\,days$ . * Dosing: Once daily. 3. Ticagrelor: * Type: Active drug (no metabolism required for activation). * Binding: Reversible. * Onset: $30\,minutes$ . * Duration: $3$ to $4\,days$ . * Dosing: Twice daily.
Drug Interactions with Clopidogrel: * Omeprazole: A common acid-suppressing drug that inhibits $CYP2C19$ . Because $CYP2C19$ is required to activate the clopidogrel pro-drug, co-administration leads to therapeutic failure. * St. John's Wort: An inducer of $CYP2C19$ . This increases the conversion of the clopidogrel pro-drug into its active form, leading to a greater antiplatelet effect.

Function of the Integrin: * $GP\,IIb/IIIa$ is an integrin found on the platelet surface. When platelets are activated, this integrin moves to the surface to interact with fibrinogen, facilitating platelet aggregation.
Mechanism of Action: * These drugs bind to the $GP\,IIb/IIIa$ receptors and prevent them from interacting with fibrinogen.
Key Agents: * Abciximab: A monoclonal antibody. * Tirofiban: A non-peptide, small drug molecule antagonist.